Bruker's innovation pipeline and acquisitions support long-term growth, but macro pressures and funding risks cloud the stock's near-term outlook.

Blood-based Biomarker for Alzheimer’s Disease Market to reach US$ 554.2 Mn by 2035 at 14.3% CAGR, driven by demand for ...

IntroductionThe global critical care diagnostics market is poised for steady expansion, projected to grow at a CAGR of around 6% over the next five years. This growth trajectory is supported by ...

Roche’s cobas BV/CV assay gains CE Mark, enabling accurate, rapid diagnosis of bacterial vaginosis and candida vaginitis.

Roche secures CE Mark approval for its automated mass spectrometry antibiotic monitoring reagents, expanding clinical ...

Fulgent Genetics ( ($FLGT) ) has shared an update. On December 20, 2025, Fulgent Genetics’ subsidiary Inform Diagnostics signed agreements to buy ...

The Delhi High Court, in a matter involving claim of Customs Duty exemption on import of Enzyme linked Immuno Absorbent Assay (ELISA) Kits for antibiotic testing in food as 'diagnostic kits' ...

Edmonton, AB – December 22, 2025 – PRESSADVANTAGE – A first in western Canada, access to TIER-1 ENDOSURE testing for the ...

Many men never see a reproductive specialist; a preventive check around age 18 — semen analysis and testicular ultrasound — ...

Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: ...

Bruker faced a tough 2024, with aggressive M&A, $600M preferred issuance, rising debt, and execution issues prompting a ...

Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from ...